Market News & Trends
Neon Therapeutics Announces Completion of Enrollment in Phase 1b Clinical Trial
Neon Therapeutics, Inc. recently announced the completion of enrollment in NT-002, its Phase 1b clinical trial evaluating NEO-PV-01 with KEYTRUDA (pembrolizumab) and chemotherapy in patients…
Thermo Fisher Scientific Announces Collaboration to Advance Biopharmaceutical Characterization & Monitoring Methods
Thermo Fisher Scientific and Genovis recently announced a collaborative research project to develop advanced end-to-end workflows for the preparation, characterization, and monitoring of novel and…
XOMA Acquires Royalty Rights to Five Hematology Candidates
XOMA Corporation recently announced it has agreed to acquire the rights to potential royalty payments and a portion of the potential milestone payments associated with…
Bellerophon Announces Agreement With FDA on Regulatory Approval Pathway for INOpulse
Bellerophon Therapeutics, Inc. recently announced it has reached agreement with the US FDA on the regulatory approval pathway for INOpulse in patients with Pulmonary Hypertension…
SomaLogic Announces New Collaboration With Janssen Research & Development
SomaLogic, Inc. recently announced it has entered into a collaborative agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson…
BioAtla & BeiGene Form Worldwide Development & Commercialization Collaboration
BioAtla , LLC and BeiGene, Ltd. recently announced the two companies have entered into a global co-development and collaboration agreement for the development, manufacturing, and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).
GeneDesign Joins Ajinomoto Bio-Pharma Services & Opens Oligonucleotide API Development Center
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced that GeneDesign, Inc. has joined the global organization.
Industry Trends: Vigilance is Critical for Future Success
Peter Soelkner says there will always be a wide variety of trends influencing our industry and we see no reason why this will not continue well into the future.
Angion Awarded $4.76-Million Department of Defense Grant for Drug Candidate
Angion Biomedica Corp. recently announced it had received a $4.76-million Department of Defense (DoD) follow-on grant for ANG-3070, its precision drug candidate for the treatment…
CytoDyn & Samsung BioLogics Enter $1-Billion Agreement
CytoDyn Inc. recently announced the execution of a comprehensive strategic agreement with Samsung BioLogics Co., Ltd. for the clinical and commercial manufacturing of leronlimab (PRO…
Moldworx Offers Unique Manufacturing Solutions to Medical Device Manufacturers
Designing solutions for medical device OEMs is the expertise of Moldworx LLC, a Gilbert, Arizona-based custom designer and builder of molds, automation solutions, and custom…
Amfora Licenses Gene-Editing Technology
Amfora recently announced it has reached a non-exclusive research and commercial license agreement with Corteva Agriscience, the Agriculture Division of DowDuPont, and the Broad Institute…
Celldex Presents Positive Interim Results From Phase 1 Study
Celldex Therapeutics, Inc. recently presented interim data from the company’s CD40 agonist program in a late-breaking poster session today at the American Association for Cancer…
Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma
Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of advanced…
CURE Pharmaceutical to Acquire Chemistry Holdings Inc.
CURE Pharmaceutical, an innovative drug delivery and development company, recently announced that it has agreed to acquire Chemistry Holdings Inc., a formulation technology company that is developing innovative delivery systems for a variety of industries, in an all-stock transaction.
Fusion Pharmaceuticals Announces $105-Million Financing
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, recently announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed.
Swissfillon AG & Früh Verpackungstechnik AG Enter Strategic Collaboration
Swissfillon AG, a provider of aseptic fill and finish services to pharmaceutical and biotechnology companies, and Früh Verpackungstechnik AG, packaging manufacturer and supplier of medical and pharmaceutical contract packaging solutions, have recently entered into a partnership.
Calithera Biosciences Initiates Phase 1/2 Trial; Part of Pfizer Collaboration
Calithera Biosciences, Inc. recently announced the first patient has been treated in the Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in…
Race Oncology Files IND With FDA for Cancer Drug
Race Oncology Limited recently announced the US Food and Drug Administration has received its Investigational New Drug (IND) application for the company’s cancer drug Bisantrene.…
Skyrizi Approval in Japan Crucial for AbbVie as Biosimilar Competition Looms Large on Humira
At a time when pricing and reimbursement pressure is mounting on its blockbuster RA drug Humira (adalimumab) in the US and biosimilar competition looms large…
